Baochun Lu

Dr. Baochun Lu


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2015 in Journal of Surgical Research
Verified
Journal Article
Closed access
JYJianhua Yu
Jianhua Yu
WZWeiguang Zhang
Weiguang Zhang
RZRongguo Zhang
Rongguo Zhang
XRXinxian Ruan
Xinxian Ruan
PRPeitu Ren
Peitu Ren
BLBaochun Lu
Baochun Lu

1 November 2015 in Toxicology Letters
Verified
Journal Article
Closed access
JYJianhua Yu
Jianhua Yu
WZWeiguang Zhang
Weiguang Zhang
RZRongguo Zhang
Rongguo Zhang
GJGuixing Jiang
Guixing Jiang
HTHaijun Tang
Haijun Tang
BLBaochun Lu
Baochun Lu

23 February 2021 in Scientific Reports
Verified
Journal Article
Open access
PDF file
CTChenhao Tong
Chenhao Tong
YWYali Wang
Yali Wang
JLJiandong Li
Jiandong Li
WCWenda Cen
Wenda Cen
WZWeiguang Zhang
Weiguang Zhang
BLBaochun Lu
Baochun Lu
Gallbladder cancer is the most common malignant tumor of the biliary system and is characterized by difficulty to diagnose in early stages, a high degree of malignancy, and poor prognosis. Finding new drugs may improve the prognosis for this dismal cancer. Herein, we investigated the potential application of pterostilbene (PTS) against gallbladder cancer in vivo and in vitro. PTS potently inhibited cell proliferation, migration and invasion of gallbladder cancer cells. Moreover, PTS also had a function of inducing apoptosis in vitro. Meanwhile, PTS reversed EMT with a correlated inhibition of PI3K/Akt activation. Tumor xenograft models showed that PTS inhibited tumor growth and had low toxicity in vivo, which were consistent with the in vitro data. These findings indicate that PTS arrests cell growth through inhibition of PI3K/AKT signaling and is a potential drug for the therapy of gallbladder cancer.

10 December 2015 in Oncology Letters
Verified
Journal Article
Open access
PDF file
ZSZhihong Shen
Zhihong Shen
XLXibo Liu
Xibo Liu
BLBaochun Lu
Baochun Lu
MYMinfeng Ye
Minfeng Ye
Hepatoid adenocarcinoma of the stomach (HAS) is a rare type of gastric cancer with an extremely poor prognosis. The current study reports a rare case of HAS, characterized by gastric cancer and infiltration of cancer cells into the left liver lobe, as well as lymphadenectasis. The expression of α‑fetoprotein (AFP) was markedly increased in the tumor cells of the liver neoplasms. A gastric biopsy indicated highly, moderately and poorly differentiated papillary adenocarcinoma. The patient underwent two cycles of chemotherapy with oxaliplatin (130 mg; day 1) and capecitabine (2 mg, twice daily; days 1‑14). At 7 weeks after the chemotherapy, an expanded gastrectomy and radical resection of left lung lobe were performed on the operable lesion. AFP expression was significantly decreased following the procedure. A literature review was also conducted by searching PubMed/Medline, indicating that surgery and chemotherapy may positively affect the outcomes of HAS patients.

1 January 2020 in BioMed Research International
Verified
Journal Article
Open access
WLWeiguo Lin
Weiguo Lin
CTChenhao Tong
Chenhao Tong
WZWeiguang Zhang
Weiguang Zhang
WCWenda Cen
Wenda Cen
YWYali Wang
Yali Wang
BLBaochun Lu
Baochun Lu
ARAF is a member of the RAF kinase family that is necessary for mitogen‐activated protein kinase (MAPK) activation in various malignancies, including lung, colorectal, pancreatic, and breast cancers. As the most common biliary tract tumor, gallbladder cancer (GBC) seriously harms human health while the function of ARAF in GBC remains elusive. Here, we found that ARAF expression was upregulated in gallbladder cancer tissues. In vitro, ARAF silencing mediated by RNA interference effectively inhibited cell proliferation, colony formation, migration, and invasion of GBC cells. Moreover, knocking down ARAF suppressed tumor growth in vivo. Our results indicated that ARAF functions as an oncogene in GBC and, thus, could be a potential therapeutic target for GBC.

21 April 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JLJiandong Li
Jiandong Li
WCWenda Cen
Wenda Cen
CTChenhao Tong
Chenhao Tong
LWLuna Wang
Luna Wang
WZWeiguang Zhang
Weiguang Zhang
BLBaochun Lu
Baochun Lu
Gallbladder cancer (GBC) is the most common biliary tract malignancy with a dismal prognosis. The development of new drugs may help to improve prognosis. This study found that fangchinoline, a bisbenzylisoquinoline alkaloids, inhibited the proliferation and clone formation of GBC cells in a dose-dependent manner. Moreover, Hoechst staining, TUNEL assays, and flow cytometry demonstrated that fangchinoline effectively induced apoptosis in GBC cells. Further studies found that an anti-apoptotic pathway, the PI3K/Akt/XIAP axis, was significantly inhibited in GBC cells after treating with fangchinoline. Finally, we confirmed that fangchinoline restrained xenograft tumor growth in vivo. Our findings indicate that fangchinoline can be considered a potential drug for GBC treatment.